Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed No phase listed Observational

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

NCT00897702
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw, immunoenzyme technique, biopsy, histopathologic examination
Other · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

NCT02260531
View directory record Official record
Conditions
Breast Cancer, Brain Tumor - Metastatic
Interventions
Cabozantinib, Trastuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 23, 2026, 2:04 PM EDT
Terminated Phase 1 Interventional Results available

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

NCT04504331
View directory record Official record
Conditions
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
Interventions
Infigratinib, Tamoxifen, Omnipaque 350, Iopamidol, Computed tomography (CT)
Drug · Diagnostic Test
Lead sponsor
Jennifer Lee Caswell-Jin
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Active, not recruiting Phase 1 Interventional

Testing a New Imaging Agent to Identify Cancer

NCT04692831
View directory record Official record
Conditions
HER-2 Positive Malignant Carcinoma of Breast, HER-2 Protein Overexpression, HER2-positive Metastatic Breast Cancer
Interventions
89Zr-ss-pertuzumab PET/CT
Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sistas Inspiring Sistas Through Activity and Support

NCT02144571
View directory record Official record
Conditions
Prevention Harmful Effects
Interventions
Lifestyle
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 23, 2026, 2:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
Interventions
177Lu-BetaBart, BetaBart + unlabeled BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Results available

Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer

NCT00121134
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Cyclophosphamide, Methotrexate, Capecitabine
Drug
Lead sponsor
Harold J. Burstein, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
San Francisco, California • Indianapolis, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 23, 2026, 2:04 PM EDT
Recruiting No phase listed Observational

Breast Mapping and Detection of Suspicious Breast Lesions Using Feminai

NCT07220863
View directory record Official record
Conditions
Breast Cancer Awareness
Interventions
Not listed
Lead sponsor
Feminai
Industry
Eligibility
25 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 23, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

NCT01528345
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dovitinib, Fulvestrant, Dovitinib Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
18
States / cities
Chandler, Arizona • Fayetteville, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

NCT01421472
View directory record Official record
Conditions
ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
Interventions
MM-121, Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 23, 2026, 2:04 PM EDT
Completed No phase listed Observational

NBRST: Prospective Neo-adjuvant REGISTRY Trial

NCT01479101
View directory record Official record
Conditions
Breast Cancer
Interventions
MammaPrint 70-gene expression profile, BluePrint 80 gene expression profile
Other
Lead sponsor
Agendia
Industry
Eligibility
18 Years to 90 Years · Female only
Enrollment
1,142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
76
States / cities
Glendale, Arizona • Scottsdale, Arizona • Berkeley, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 23, 2026, 2:04 PM EDT
Recruiting No phase listed Observational

Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

NCT07675967
View directory record Official record
Conditions
Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers, Breast Cancer, Gastric (Stomach) Cancer, Colorectal (Colon or Rectal) Cancer, Sarcoma, Ovarian Adenocarcinoma, Uterine Adenocarcinoma, Endometrial Adenocarcinoma, Esophageal Adenocarcinoma, Head and Neck Cancer, Therapy-Related Acute Myeloid Leukemia, Therapy-Related MDS, Clonal Hematopoiesis of Indeterminate Potential (CHIP), Clonal Cytopenia of Undetermined Significance
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Not listed No phase listed Observational

Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer

NCT01148407
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 23, 2026, 2:04 PM EDT
Withdrawn Phase 2 Interventional

Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer

NCT00003536
View directory record Official record
Conditions
Stage IV Breast Cancer, Recurrent Breast Cancer
Interventions
antineoplaston A10, methotrexate, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, chemotherapy, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 23, 2026, 2:04 PM EDT
Not listed No phase listed Observational

Outcomes After Perforator Flap Reconstruction for Breast Reconstruction and/or Lymphedema Treatment

NCT01273909
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Acquired Lymphedema, Congenital Lymphedema
Interventions
Perforator Flap Breast Reconstruction, Vascularized Lymph Node Transfer
Procedure
Lead sponsor
The National Institute of Lymphology
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Chicago, Illinois • New Orleans, Louisiana • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 23, 2026, 2:04 PM EDT
Completed No phase listed Observational

Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer

NCT03749421
View directory record Official record
Conditions
Breast Cancer
Interventions
Prosigna PAM-50 assay
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Overcoming Racial Disparities in Screening Mammography

NCT07549139
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Appointment mail reminder, Telephone counseling, Digital navigation video, Automated phone call
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Results available

Single Dose Partial Breast Radiotherapy

NCT00944528
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiosurgery
Radiation
Lead sponsor
Duke University
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Aquatic Exercise Study for Breast Cancer Patients With Lymphedema

NCT00498771
View directory record Official record
Conditions
Lymphedema
Interventions
Aquatic Exercise arm
Behavioral
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Southeast Asian Women's Health Project

NCT04086771
View directory record Official record
Conditions
Breast Cancer, Cervical Cancer
Interventions
Navigation, Information only
Behavioral · Other
Lead sponsor
Ohio State University
Other
Eligibility
21 Years and older · Female only
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial For Patients With Metastatic Breast Cancer

NCT00191152
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Cancer of the Breast
Interventions
gemcitabine, docetaxel, capecitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
47
States / cities
Glendale, Arizona • Fort Smith, Arkansas • Hot Springs, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2009 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy

NCT01941784
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
educational intervention, counseling intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment
Other · Behavioral · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 23, 2026, 2:04 PM EDT
Completed Not applicable Interventional

Living Well After Breast Surgery

NCT03834532
View directory record Official record
Conditions
Breast Cancer Female, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Ductal Carcinoma in Situ, Ductal Breast Carcinoma, Lobular Breast Carcinoma
Interventions
Breast reconstruction decision aid, Educational website
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 2:04 PM EDT